This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Niehans, G. A. Articles by Kratzke, R. A. Search for Related Content PubMed PubMed Citation Articles by Niehans, G. A. Articles by Kratzke, R. A.

Human Lung Carcinomas Express Fas Ligand¹

Department of Pathology [G.A.N., D.J.K.], Department of Medicine, Section of Hematology/Oncology [S.P.F., J.C.L., R.A.K.], and Department of Surgery [C.T.S.], Minneapolis Veterans Affairs Medical Center and the University of Minnesota Medical School, Minneapolis, Minnesota 55417, and La Jolla Institute of Allergy and Immunology, San Diego, California 92121 [T.B., D.R.G.]

To reach a clinically detectable size, neoplasms must be able to suppress or evade a host immune response. Activated T cells may enter apoptosis in the presence of Fas ligand (FasL) (1), and tissue expression of FasL has been shown to contribute to immune privilege in the eye and testis (2, 3). We have demonstrated that all human lung carcinoma cell lines tested (16 of 16) express a M_r 38,000 protein consistent with FasL by immunoblotting, whereas the majority of resected tumors (23 of 28) show positive staining for FasL by immunohistochemistry. DNA sequencing of reverse transcription-PCR products from lung cancer cells and resected lung tumors confirms the presence of human FasL mRNA in these neoplastic tissues. Furthermore, lung carcinoma cells are capable of killing a Fassensitive human T cell line (Jurkat) in coculture experiments; this killing was inhibited by a recombinant form of the soluble portion of the Fas receptor (FasFc). FasL expression by neoplastic cells represents a potential mechanism for peripheral deletion of tumor-reactive T-cell clones.

¹ Supported by a Research Advisory Group grant from the Department of Veterans Affairs (to R. A. K.) and Grant GM2735 (to D. R. G.) from the NIH, Bethesda, MD. T. B. is a fellow of the Swiss Foundation for Medical-Biological Fellowships.

² To whom requests for reprints should be addressed, at Hematology/Oncology 111E, Minneapolis V. A. Medical Center, 1 Veterans Drive, Minneapolis, MN 55417. Phone: (612) 725-2000, ext. 4135; E-mail: kratzke.robert@minneapolis.va.gov.

Received 11/26/96. Accepted 1/27/97.

This article has been cited by other articles:

				C.-C. Su, Y.-P. Lin, Y.-J. Cheng, J.-Y. Huang, W.-J. Chuang, Y.-S. Shan, and B.-C. Yang Phosphatidylinositol 3-Kinase/Akt Activation by Integrin-Tumor Matrix Interaction Suppresses Fas-Mediated Apoptosis in T Cells J. Immunol., October 1, 2007; 179(7): 4589 - 4597. [Abstract] [Full Text] [PDF]

				Y. Tesfaigzi Roles of Apoptosis in Airway Epithelia Am. J. Respir. Cell Mol. Biol., May 1, 2006; 34(5): 537 - 547. [Abstract] [Full Text] [PDF]

				B. A. Jacobson, M. D. Alter, M. G. Kratzke, S. P. Frizelle, Y. Zhang, M. S. Peterson, S. Avdulov, R. P. Mohorn, B. A. Whitson, P. B. Bitterman, et al. Repression of Cap-Dependent Translation Attenuates the Transformed Phenotype in Non-Small Cell Lung Cancer Both In vitro and In vivo. Cancer Res., April 15, 2006; 66(8): 4256 - 4262. [Abstract] [Full Text] [PDF]

				A. E. Ryan, F. Shanahan, J. O'Connell, and A. M. Houston Addressing the "Fas Counterattack" Controversy: Blocking Fas Ligand Expression Suppresses Tumor Immune Evasion of Colon Cancer In vivo Cancer Res., November 1, 2005; 65(21): 9817 - 9823. [Abstract] [Full Text] [PDF]

				X Zhang, X Miao, T Sun, W Tan, S Qu, P Xiong, Y Zhou, and D Lin Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer J. Med. Genet., June 1, 2005; 42(6): 479 - 484. [Abstract] [Full Text] [PDF]

				F. Donskov, H. von der Maase, N. Marcussen, S. Hamilton-Dutoit, H. H. T. Madsen, J. J. Jensen, and M. Hokland Fas Ligand Expression in Metastatic Renal Cell Carcinoma During Interleukin-2 Based Immunotherapy: No In vivo Effect of Fas Ligand Tumor Counterattack Clin. Cancer Res., December 1, 2004; 10(23): 7911 - 7916. [Abstract] [Full Text] [PDF]

				O. Bohana-Kashtan and C. I. Civin Fas Ligand as a Tool for Immunosuppression and Generation of Immune Tolerance Stem Cells, November 1, 2004; 22(6): 908 - 924. [Abstract] [Full Text] [PDF]

				Y.-L. Chen, S.-H. Chen, J.-Y. Wang, and B.-C. Yang Fas Ligand on Tumor Cells Mediates Inactivation of Neutrophils J. Immunol., August 1, 2003; 171(3): 1183 - 1191. [Abstract] [Full Text] [PDF]

				E. Sapi, W. D. Brown, S. Aschkenazi, C. Lim, A. Munoz, B. M. Kacinski, T. Rutherford, and G. Mor Regulation of Fas Ligand Expression By Estrogen in Normal Ovary Reproductive Sciences, July 1, 2002; 9(4): 243 - 250. [Abstract] [PDF]

				M. Suzuoki, Y. Hida, M. Miyamoto, T. Oshikiri, K. Hiraoka, Y. Nakakubo, T. Shinohara, T. Itoh, S. Okushiba, S. Kondo, et al. RCAS1 Expression as a Prognostic Factor After Curative Surgery for Extrahepatic Bile Duct Carcinoma Ann. Surg. Oncol., May 1, 2002; 9(4): 388 - 393. [Abstract] [Full Text] [PDF]

				J. Song, T. Rutherford, F. Naftolin, S. Brown, and G. Mor Hormonal regulation of apoptosis and the Fas and Fas ligand system in human endometrial cells Mol. Hum. Reprod., May 1, 2002; 8(5): 447 - 455. [Abstract] [Full Text] [PDF]

				C. Zietz, U. Rumpler, M. Sturzl, and U. Lohrs Inverse Relation of Fas-Ligand and Tumor-Infiltrating Lymphocytes in Angiosarcoma : Indications of Apoptotic Tumor Counterattack Am. J. Pathol., September 1, 2001; 159(3): 963 - 970. [Abstract] [Full Text] [PDF]

				M W Bennett, J O'Connell, A Houston, J Kelly, G C O'Sullivan, J K Collins, and F Shanahan Fas ligand upregulation is an early event in colonic carcinogenesis J. Clin. Pathol., August 1, 2001; 54(8): 598 - 604. [Abstract] [Full Text] [PDF]

				D. Zagury, A. Burny, and R. C. Gallo Toward a new generation of vaccines: The anti-cytokine therapeutic vaccines PNAS, July 3, 2001; 98(14): 8024 - 8029. [Abstract] [Full Text] [PDF]

				S. L. Starcevic, C. Elferink, and R. F. Novak Progressive Resistance to Apoptosis in a Cell Lineage Model of Human Proliferative Breast Disease J Natl Cancer Inst, May 16, 2001; 93(10): 776 - 782. [Abstract] [Full Text] [PDF]

				B. JOSEPH, R. LEWENSOHN, and B. ZHIVOTOVSKY Role of Apoptosis in the Response of Lung Carcinomas to Anti-Cancer Treatment Ann. N.Y. Acad. Sci., December 1, 2000; 926(1): 204 - 216. [Abstract] [Full Text] [PDF]

				S.-Y. Sun, P. Yue, W. K. Hong, and R. Lotan Induction of Fas Expression and Augmentation of Fas/Fas Ligand-mediated Apoptosis by the Synthetic Retinoid CD437 in Human Lung Cancer Cells Cancer Res., November 15, 2000; 60(22): 6537 - 6543. [Abstract] [Full Text] [PDF]

				T. Waku, T. Fujiwara, J. Shao, T. Itoshima, T. Murakami, M. Kataoka, S. Gomi, J. A. Roth, and N. Tanaka Contribution of CD95 Ligand-Induced Neutrophil Infiltration to the Bystander Effect in p53 Gene Therapy for Human Cancer J. Immunol., November 15, 2000; 165(10): 5884 - 5890. [Abstract] [Full Text] [PDF]

				C. M. Mueller and D. W. Scott Distinct Molecular Mechanisms of Fas Resistance in Murine B Lymphoma Cells J. Immunol., August 15, 2000; 165(4): 1854 - 1862. [Abstract] [Full Text] [PDF]

				N. Favre-Felix, A. Fromentin, A. Hammann, E. Solary, F. Martin, and B. Bonnotte Cutting Edge: The Tumor Counterattack Hypothesis Revisited: Colon Cancer Cells Do Not Induce T Cell Apoptosis Via the Fas (CD95, APO-1) Pathway J. Immunol., May 15, 2000; 164(10): 5023 - 5027. [Abstract] [Full Text] [PDF]

				A.-K. Eerola, Y. Soini, and P. Pääkkö A High Number of Tumor-infiltrating Lymphocytes Are Associated with a Small Tumor Size, Low Tumor Stage, and a Favorable Prognosis in Operated Small Cell Lung Carcinoma Clin. Cancer Res., May 1, 2000; 6(5): 1875 - 1881. [Abstract] [Full Text]

				A. M. Hohlbaum, S. Moe, and A. Marshak-Rothstein Opposing Effects of Transmembrane and Soluble Fas Ligand Expression on Inflammation and Tumor Cell Survival J. Exp. Med., April 3, 2000; 191(7): 1209 - 1220. [Abstract] [Full Text] [PDF]

				T. L. Weigel, M. T. Lotze, P. K. Kim, A. A. Amoscato, J. D. Luketich, and C. Odoux PACLITAXEL-INDUCED APOPTOSIS IN NON-SMALL CELL LUNG CANCER CELL LINES IS ASSOCIATED WITH INCREASED CASPASE-3 ACTIVITY J. Thorac. Cardiovasc. Surg., April 1, 2000; 119(4): 795 - 803. [Abstract] [Full Text] [PDF]

				W. A. Chow, J. J. Fang, and J.-K. Yee The IFN Regulatory Factor Family Participates in Regulation of Fas Ligand Gene Expression in T Cells J. Immunol., April 1, 2000; 164(7): 3512 - 3518. [Abstract] [Full Text] [PDF]

				T. Brunner, S. Kasibhatla, M. J. Pinkoski, C. Frutschi, N. J. Yoo, F. Echeverri, A. Mahboubi, and D. R. Green Expression of Fas Ligand in Activated T Cells Is Regulated by c-Myc J. Biol. Chem., March 24, 2000; 275(13): 9767 - 9772. [Abstract] [Full Text] [PDF]

				B. R. Gastman, D. E. Johnson, T. L. Whiteside, and H. Rabinowich Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events Blood, March 15, 2000; 95(6): 2015 - 2023. [Abstract] [Full Text] [PDF]

				H. Shinohara, H. Yagita, Y. Ikawa, and N. Oyaizu Fas Drives Cell Cycle Progression in Glioma Cells via Extracellular Signal-regulated Kinase Activation Cancer Res., March 1, 2000; 60(6): 1766 - 1772. [Abstract] [Full Text]

				T. Reimer, C. Herrnring, D. Koczan, D. Richter, B. Gerber, D. Kabelitz, K. Friese, and H.-J. Thiesen FasL:Fas Ratio-A Prognostic Factor in Breast Carcinomas Cancer Res., February 1, 2000; 60(4): 822 - 828. [Abstract] [Full Text]

				K. Kelly, E. Manos, G. Jensen, L. Nadauld, and D. A. Jones APRIL/TRDL-1, a Tumor Necrosis Factor-like Ligand, Stimulates Cell Death Cancer Res., February 1, 2000; 60(4): 1021 - 1027. [Abstract] [Full Text]

				K. Walsh and J. M. Isner Apoptosis in inflammatory-fibroproliferative disorders of the vessel wall Cardiovasc Res, February 1, 2000; 45(3): 756 - 765. [Abstract] [Full Text] [PDF]

				C. G. Ferreira, C. Tolis, S. W. Span, G. J. Peters, T. van Lopik, A. J. Kummer, H. M. Pinedo, and G. Giaccone Drug-induced Apoptosis in Lung Cancer Cells Is Not Mediated by the Fas/FasL (CD95/APO1) Signaling Pathway Clin. Cancer Res., January 1, 2000; 6(1): 203 - 212. [Abstract] [Full Text]

				K. M. Fong, Y. Sekido, and J. D. Minna MOLECULAR PATHOGENESIS OF LUNG CANCER J. Thorac. Cardiovasc. Surg., December 1, 1999; 118(6): 1136 - 1152. [Abstract] [Full Text] [PDF]

				I. Durieu, C. Amsellem, C. Paulin, M.-T. Chambe, J. Bienvenu, G. Bellon, and Y Pacheco Fas and Fas ligand expression in cystic fibrosis airway epithelium Thorax, December 1, 1999; 54(12): 1093 - 1098. [Abstract] [Full Text]

				N. Mitsiades, V. Poulaki, A. Leone, and M. Tsokos Fas-Mediated Apoptosis in Ewing's Sarcoma Cell Lines by Metalloproteinase Inhibitors J Natl Cancer Inst, October 6, 1999; 91(19): 1678 - 1684. [Abstract] [Full Text] [PDF]

				B. R. Gastman, Y. Atarashi, T. E. Reichert, T. Saito, L. Balkir, H. Rabinowich, and T. L. Whiteside Fas Ligand Is Expressed on Human Squamous Cell Carcinomas of the Head and Neck, and It Promotes Apoptosis of T Lymphocytes Cancer Res., October 1, 1999; 59(20): 5356 - 5364. [Abstract] [Full Text] [PDF]

				R. M. Bukowski, P. Rayman, L. Molto, C. S. Tannenbaum, T. Olencki, D. Peereboom, R. Tubbs, D. McLain, G. T. Budd, T. Griffin, et al. Interferon-{{gamma}} and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma Clin. Cancer Res., October 1, 1999; 5(10): 2780 - 2789. [Abstract] [Full Text] [PDF]

				M. Shibakita, M. Tachibana, D. K. Dhar, T. Kotoh, S. Kinugasa, H. Kubota, R. Masunaga, and N. Nagasue Prognostic Significance of Fas and Fas Ligand Expressions in Human Esophageal Cancer Clin. Cancer Res., September 1, 1999; 5(9): 2464 - 2469. [Abstract] [Full Text] [PDF]

				N. Mitsiades, V. Poulaki, G. Mastorakos, S. Tseleni-Balafouta, V. Kotoula, D. A. Koutras, and M. Tsokos Fas Ligand Expression in Thyroid Carcinomas: A Potential Mechanism of Immune Evasion J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2924 - 2932. [Abstract] [Full Text]

				R. K. Srivastava, C. Y. Sasaki, J. M. Hardwick, and D. L. Longo Bcl-2–mediated Drug Resistance: Inhibition of Apoptosis by Blocking Nuclear Factor of Activated T Lymphocytes (NFAT)-induced Fas Ligand Transcription J. Exp. Med., July 19, 1999; 190(2): 253 - 266. [Abstract] [Full Text] [PDF]

				J. O'Connell, M. W. Bennett, G. C. O'Sullivan, J. O'Callaghan, J. K. Collins, and F. Shanahan Expression of Fas (CD95/APO-1) Ligand by Human Breast Cancers: Significance for Tumor Immune Privilege Clin. Vaccine Immunol., July 1, 1999; 6(4): 457 - 463. [Abstract] [Full Text] [PDF]

				G. MOALEM, A. MONSONEGO, Y. SHANI, I. R. COHEN, and M. SCHWARTZ Differential T cell response in central and peripheral nerve injury: connection with immune privilege FASEB J, July 1, 1999; 13(10): 1207 - 1217. [Abstract] [Full Text]

				M. Shimizu, A. Fontana, Y. Takeda, H. Yagita, T. Yoshimoto, and A. Matsuzawa Induction of Antitumor Immunity with Fas/APO-1 Ligand (CD95L)-Transfected Neuroblastoma Neuro-2a Cells J. Immunol., June 15, 1999; 162(12): 7350 - 7357. [Abstract] [Full Text] [PDF]

				T. Saito, I. Kuss, G. Dworacki, W. Gooding, J. T. Johnson, and T. L. Whiteside Spontaneous ex Vivo Apoptosis of Peripheral Blood Mononuclear Cells in Patients with Head and Neck Cancer Clin. Cancer Res., June 1, 1999; 5(6): 1263 - 1273. [Abstract] [Full Text] [PDF]

				R. G. Uzzo, P. Rayman, V. Kolenko, P. E. Clark, T. Bloom, A. M. Ward, L. Molto, C. Tannenbaum, L. J. Worford, R. Bukowski, et al. Mechanisms of Apoptosis in T Cells from Patients with Renal Cell Carcinoma Clin. Cancer Res., May 1, 1999; 5(5): 1219 - 1229. [Abstract] [Full Text] [PDF]

				T. Z. Zaks, D. B. Chappell, S. A. Rosenberg, and N. P. Restifo Fas-Mediated Suicide of Tumor-Reactive T Cells Following Activation by Specific Tumor: Selective Rescue by Caspase Inhibition J. Immunol., March 15, 1999; 162(6): 3273 - 3279. [Abstract] [Full Text] [PDF]

				A. Morelli, A. Larregina, J Smith-Arica, R. Dewey, T. Southgate, B Ambar, A Fontana, M. Castro, and P. Lowenstein Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity J. Gen. Virol., March 1, 1999; 80(3): 571 - 583. [Abstract]

				M W Bennett, J O'Connell, G C O'Sullivan, D Roche, C Brady, J Kelly, J K Collins, and F Shanahan Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer Gut, February 1, 1999; 44(2): 156 - 162. [Abstract] [Full Text] [PDF]

				Y.-Y. Mo and W. T. Beck DNA Damage Signals Induction of Fas Ligand in Tumor Cells Mol. Pharmacol., February 1, 1999; 55(2): 216 - 222. [Abstract] [Full Text]

				M. Muller, S. Wilder, D. Bannasch, D. Israeli, K. Lehlbach, M. Li-Weber, S. L. Friedman, P. R. Galle, W. Stremmel, M. Oren, et al. p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs J. Exp. Med., December 7, 1998; 188(11): 2033 - 2045. [Abstract] [Full Text] [PDF]

				N. Mitsiades, V. Poulaki, V. Kotoula, A. Leone, and M. Tsokos Fas Ligand Is Present in Tumors of the Ewing's Sarcoma Family and Is Cleaved into a Soluble Form by a Metalloproteinase Am. J. Pathol., December 1, 1998; 153(6): 1947 - 1956. [Abstract] [Full Text] [PDF]

				L. B. Owen-Schaub, K. L. van Golen, L. L. Hill, and J. E. Price Fas and Fas Ligand Interactions Suppress Melanoma Lung Metastasis J. Exp. Med., November 2, 1998; 188(9): 1717 - 1723. [Abstract] [Full Text] [PDF]

				K. J. Hamann, D. R. Dorscheid, F. D. Ko, A. E. Conforti, A. I. Sperling, K. F. Rabe, and S. R. White Expression of Fas (CD95) and FasL (CD95L) in Human Airway Epithelium Am. J. Respir. Cell Mol. Biol., October 1, 1998; 19(4): 537 - 542. [Abstract] [Full Text]

				M. W. Bennett, J. O'Connell, G. C. O'Sullivan, C. Brady, D. Roche, J. K. Collins, and F. Shanahan The Fas Counterattack In Vivo: Apoptotic Depletion of Tumor-Infiltrating Lymphocytes Associated with Fas Ligand Expression by Human Esophageal Carcinoma J. Immunol., June 1, 1998; 160(11): 5669 - 5675. [Abstract] [Full Text] [PDF]

				C. Beltinger, E. Kurz, T. Bohler, M. Schrappe, W.-D. Ludwig, and K.-M. Debatin CD95 (APO-1/Fas) Mutations in Childhood T-Lineage Acute Lymphoblastic Leukemia Blood, May 15, 1998; 91(10): 3943 - 3951. [Abstract] [Full Text] [PDF]

				T. A. Stokes, M. Rymaszewski, P. L. Arscott, S. H. Wang, J. D. Bretz, J. Bartron, J. R. Baker Jr.;, P. Fiedler, C. E. Schaetzlein, H. Eibel;, et al. Constitutive Expression of FasL in Thyrocytes Science, March 27, 1998; 279(5359): 2015 - 2015. [Full Text]

				B. R. Gochuico, K. M. Miranda, E. M. Hessel, J. J. De Bie, A. J. M. Van Oosterhout, W. W. Cruikshank, and A. Fine Airway epithelial Fas ligand expression: potential role in modulating bronchial inflammation Am J Physiol Lung Cell Mol Physiol, March 1, 1998; 274(3): L444 - L449. [Abstract] [Full Text] [PDF]

				C. M. Eischen, T. J. Kottke, L. M. Martins, G. S. Basi, J. S. Tung, W. C. Earnshaw, P. J. Leibson, and S. H. Kaufmann Comparison of Apoptosis in Wild-Type and Fas-Resistant Cells: Chemotherapy-Induced Apoptosis Is Not Dependent on Fas/Fas Ligand Interactions Blood, August 1, 1997; 90(3): 935 - 943. [Abstract] [Full Text] [PDF]